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Summary statement 
Myosin binding protein-C, which mediates sarcomeric diseases such as hypertrophic 
cardiomyopathy, functionally interacts with the cardiac Ca2+ release channel (RyR2), 
representing potential novel retrograde regulation mechanism for muscle excitation-
contraction coupling.  
 
Abstract 
Cardiac ryanodine receptor (RyR2) mediates the sarcoplasmic reticulum (SR) Ca2+ efflux that 
induces cardiomyocyte contraction, whereas cardiac myosin binding protein-C (cMyBP-C) 
regulates actomyosin cross-bridge cycling. We report the first evidence for existence of a 
RyR2:cMyBP-C complex direct interaction between these two using several complementary 
methods. . Our studies indicate the C-terminus of cMyBP-C binds to the RyR2 N-terminus in 
mammalian cells with minimal requirement of a fibronectin-like type 3 domain. Importantly, 
we observe that specific binding between both recombinant cMyBP-C and RyR2 also occurs 
with the native proteins extracted from cardiac tissue. Co-expression of cMyBP-C and RyR2 
in HEK293 cells alters cellular Ca2+ dynamics, with reduced frequency of RyR2-mediated 
spontaneous Ca2+ oscillations, suggesting a potential inhibitory effect of cMyBP-C on RyR2 
Ca2+ release. Our discovery of direct, functional cMyBP-C association with RyR2 provides 
novel evidence for putative linkage between cytosolic soluble cMyBP-C and SR-mediated Ca2+ 
release via RyR2, with possible relevance to cMyBP-C and RyR2 dysfunction observed in 
inherited cardiac disorders.  
 
  
Introduction 
Cardiac muscle excitation-contraction coupling, where the electrical depolarisation stimulus of 
cardiomyocytes plasma membrane triggers mechanical contraction of the heart, is mediated by 
Ca2+-induced Ca2+-release, where small influx of Ca2+ into the cytoplasm results in release of 
Ca2+ from SR. When the heart is in the diastolic (relaxation) phase, intracellular Ca2+ is 
sequestered into the sarcoplasmic reticulum (SR), the major internal Ca2+ store of the 
cardiomyocyte. During systole (contraction phase), plasma membrane electrical excitation 
causes Ca2+ influx through coordinated opening of voltage-gated Ca2+ channels, leading to a 
global efflux of Ca2+ from the SR via the SR-located Ca2+ release channel-ryanodine receptor 
2 complex (RyR2), which in turn induces sarcomere shortening (Bers, 2002). Physiological 
regulation of muscle contraction involves the control of acto-myosin cross-bridge cycling, 
which is initiated by Ca2+ binding to troponin, thus allowing the myosin thick-filament protein 
to interact with actin, the thin-filament protein. The force and frequency of muscle contraction 
is influenced by numerous factors including sarcomere Ca2+ responsiveness, phosphorylation 
and various modulatory proteins; amongst the latter is myosin binding protein C (MyBP-C), 
an important protein that plays a vital modulatory role (Clark et al., 2002; Moss et al., 2015). 
The three mammalian RyR protein isoforms (skeletal RyR1, cardiac RyR2 and expressed in 
various tissues RyR3) share ~65% sequence identity, with the concensus RyR oligomeric 
structure composed of four identical subunits surrounding a centrally-located Ca2+ ion channel 
pore entailing the C-terminal transmembrane domains of each protomer. In contrast, the much 
larger cytoplasmic N-terminal assembly serves as a binding scaffold for myriad accessory 
proteins, ions, and other regulatory molecules (Lanner et al., 2010). Modulation of RyR 
channel opening and closing by stimulatory/inhibitory cytoplasmic signals is mediated by long-
range conformational changes involving the interplay between N- and C-terminal domains 
within a single RyR subunit, as well as between neighbouring subunits of the RyR tetramer 
(Seidel et al., 2015a). Given the essential role of RyR in enabling SR Ca2+ release, it is 
unsurprising that RyR functional alterations are associated with human disease (Lanner et al., 
2010). Thus, RyR1 mutations are linked to skeletal muscle disorders including malignant 
hyperthermia and central core disease, while RyR2 mutations have a direct causative role in 
the heart rhythm disorders, catecholaminergic polymorphic ventricular tachycardia (CPVT) 
and arrhythmogenic right ventricular dysplasia (ARVD), and discrete RyR2 mutations have 
also been recently implicated in dilated cardiomyopathy (DCM) (Haas et al., 2014). 
MyBP-C is an immunoglobulin (Ig) protein superfamily member and exists in three isoforms: 
cardiac (cMyBP-C, exclusively heart-expressed), and fast- & slow-skeletal muscle types, with 
an overall peptide sequence identity of ~55%. All three isoforms share common architectural 
features, comprising ten globular domains designated C1-C10, seven of which are Ig-like 
domains with the remaining three categorized as fibronectin-like (Fn) type-3 domains. Notably, 
cMyBP-C contains an additional Ig domain (C0) at the extreme N-terminus, a phosphorylation 
motif in the M domain and an insertion within C5 (Moss et al., 2015; Sadayappan and de 
Tombe, 2012; Sequeira et al., 2014). The C-terminal domains are responsible for anchoring 
cMyBP-C to the thick filament, while the N-terminus is thought to be involved in the 
interaction with both myosin and actin. Extensive cMyBP-C phosphorylation contributes to 
myosin head alignment & extension towards the thin filaments, thus producing strong actin-
myosin interactions and enhanced contractile output. Abnormalities in cMyBP-C are also 
associated with cardiac disease pathogenesis. Dephosphorylation of cMyBP-C enhances its 
dissociation from the sarcomere into the bulk cytoplasm (Govindan et al., 2012), a cMyBP-C 
feature that is observed in animal models of heart failure and pathologic hypertrophy (Sequeira 
et al., 2014). Moreover, dominant mutations in slow MyBP-C have been linked to the 
development of distal arthrogryposis (Geist and Kontrogianni-Konstantopoulos, 2016), while 
cMyBP-C mutations have been reported in hypertrophic cardiomyopathy (HCM), DCM and 
left ventricular non-compaction (Carrier et al., 2015). 
Impaired muscle relaxation and the alteration of sub-cellular Ca2+ signalling are common 
features in several cMyBP-C animal models (Brickson et al., 2007; Pohlmann et al., 2007; 
Song et al., 2003), pointing to a role for cMyBP-C as a multifaceted signalling node in myocyte 
function that contributes to assembly, stabilization and regulation of sarcomere shortening, as 
well as to the critical modulation of Ca2+ homeostasis. Here, we present several lines of 
evidence that suggests cMyBP-C influences cardiomyocyte intracellular Ca2+ signalling via a 
novel stoichiometric interaction with RyR2 Ca2+ release channels. 
 
Results 
Identification of cMyBP-C as a novel RyR2-binding protein 
To identify novel RyR2-binding proteins, we employed the yeast two-hybrid (Y2H) system 
using an RyR2 N-terminal fragment (residues 1-906, BT4L; RyR2NT) as the “bait” to screen a 
human heart cDNA library. Several positive clones were found by nucleotide sequence analysis 
to encode the C-terminus (residues 817-1274) of cMyBP-C (cMyBP-CCT). When the isolated 
cMyBP-CCT clone was screened against a series of overlapping fragments covering the entire 
length of RyR2, a positive interaction was detected only for RyR2NT (Table 1), demonstrating 
the RyR2 N-terminal1-906 domain-specificity of cMyBP-CCT binding. 
To reinforce our Y2H observations, putative binding of RyR2 to cMyBP-C was assessed by 
co-IP following co-expression of distinct fusion constructs in mammalian HEK293 cells, an 
immortalised cell lineage devoid of RyR2 and cMyBP-C. Thus, HA-tagged cMyBP-CCT was 
immunoprecipitated using AbHA and verified by immunoblotting (Fig. 1A, bottom panel), 
while the presence of co-precipitated cMyc-tagged RyR2NT was analysed by immunoblotting 
with AbcMyc. The co-IP revealed that RyR2NT was recovered in the AbHA immunoprecipitate 
but not in the rabbit IgG control (Fig. 1A), suggesting interaction between the recombinant 
proteins, RyR2NT and cMyBP-CCT. Consistent with the Y2H data (Table 1), parallel co-IP 
experiments revealed no interaction of cMyBP-C with BT7 (Fig. 1A), a RyR2 central region 
construct (residues 3071-3940) of similar size to BT4L. RyR2NT was also tested for an 
interaction either with full-length cMyBP-C (cMyBP-CFL) or a large N-terminal fragment 
comprising domains C0-C6 (NT, residues 1-865; cMyBP-CNT). Distinctive RyR2NT co-
precipitation was observed when co-expressed with cMyBP-CFL but was negligible for 
cMyBP-CNT (Fig. 1B & C). Densitometric analysis indicates equivalent specific binding of 
RyR2NT with cMyBP-CFL and cMyBP-CCT (Fig. 1D). In contrast, RyR2NT binding to cMyBP-
CNT, as well as BT7 binding for any cMyBP-C construct, was minimal (Fig. 1D). These results 
indicate that RyR2 complexes with cMyBP-C in vitro via the cMyBP-C C-terminus domain’s 
interaction with the RyR2 N-terminus. 
Given the high levels of sequence conservation across all three isoforms of MyBP-C C-termini 
(~70%), as well as for the N-termini of all three RyR isoforms (>80%), the RyR1 and RyR3 
N-terminal fragments (BT4LR1, aa 1-915; RyR1NT and BT4LR3, aa 1-911; RyR3NT) were also 
tested for cMyBP-CCT binding by co-IP assays. Interaction of cMyBP-CCT with both RyR1NT 
and RyR3NT was observed, comparable to that of RyR2NT (Fig. S2), suggesting that 
RyR:MyBP-C association may occur in both cardiac and skeletal muscle. 
 
Fibronectin-like type 3 domains mediate robust RyR2:cMyBP-C interaction 
To determine the RyR2-binding site within cMyBP-CCT, which comprises part of C6 and the 
C7-C10 domains (Fig. 2A), ten overlapping cMyBP-CCT sub-fragments were generated having 
boundaries within linker sequences between discrete structural domains to facilitate correct 
protein folding (Fig. 2A). Since the cMyBP-CCT isolated by Y2H screen contained only part of 
domain C6, cMyBP-C constructs encoding the whole C6 domain (fC6) were also prepared. 
Thus, co-IP assays (n ≥ 5) with HEK293 cell lysates co-expressing HA-tagged cMyBP-C 
constructs and RyR2NT (Fig. 2B) were undertaken. Both the overlapping triple-domain 
constructs, C6-C8 & C8-C10, displayed interaction with RyR2NT, with a ~3-fold stronger 
signal for C6-C8 versus C8-C10. Further double-domain constructs C6-C7/fC6-C7, C8-C9 and 
C9-C10 also exhibited RyR2NT binding, providing the apparent rank order; C6-C8≈C6-C7 > 
C8-C10≈C9-C10 >> C8-C9. These results suggest a Fn domain requirement for the cMyBP-
RyR2NT interaction, C7 in particular and then for C9, which share 36% sequence identity. 
Domain C6, which appears to be dispensable since cMyBP-CNT exhibited minimal RyR2NT 
binding, has lower sequence identity with C7 and C9 (22% and 24%, respectively). Notably, 
individual domains C7 and C9 (as well as fC6, C8) displayed negligible RyR2NT binding, 
suggesting that two domains are minimally required either to comprise the appropriate 
conformation or to jointly contribute the RyR2 binding interface. 
Similarly, to further map the cMyBP-C binding site within the RyR2 N-terminus, a series of 
eight overlapping cMyc-tagged RyR2NT sub-fragments (Fig. 2C) were co-expressed together 
with cMyBP-CCT in HEK293 cells for co-IP assays. Quantitative (n ≥ 5) densitometry and 
statistical analysis indicates that RyR2NT sub-fragments BT4 (residues 1-759), BT4D (residues 
161-759), BT4DL (residues 161-906) and BT4EL (residues 565-906) retain significant 
cMyBP-C binding (compared to their respective non-specific binding, p < 0.05), albeit binding 
was reduced relative to RyR2NT (Fig. 2D). These results suggest multiple determinants within 
the RyR2 N-terminus are necessary for robust interaction with cMyBP-C. 
 
Native porcine cardiac and recombinant human RyR2:cMyBP-C association 
Further to demonstrating cMyBP-CCT interaction with RyR2NTin an heterologous expression 
system (yeast), we sought to identify the putative RyR2:cMyBP-C association in native 
mammalian tissue. Initially, we investigated cMyBP-C expression in the SR compartment, 
using porcine cardiac SR and antibodies raised against either the cMyBP-C N-terminus or C-
terminus (AbC-NT and AbC-CT, respectively; Fig. S3). Following subcellular fractionation, a 
proportion of soluble cMyBP-C was detected in the cytosol. Significantly, substantial amounts 
of cMyBP-C co-migrated with the SR fraction suggesting association with an SR-resident 
moiety(ies), potentially RyR2. To address such possibility, we performed RyR2 co-IP 
experiments using solubilised pig cardiac tissue (with RyR2-specific Ab1093) and co-
precipitated cMyBP-C was monitored (using AbC-CT; Fig. 3A&B). We determined that 
cMyBP-C was readily detected upon RyR2 immuno-isolation, with statistically-significant 
specific binding between the native proteins (p < 0.05).  
Parallel experiments using HEK293 cells co-expressing both the human proteins further 
demonstrated significant (p < 0.05) specific interaction between the recombinant human RyR2 
and cMyBP-C (Fig. 3C&D). Moreover, the co-immunolocalization observed for recombinant 
human RyR2 and cMyBP-C is consistent with potential subcellular interaction between these 
proteins (Fig. 4A). The proportion of RyR2-positive voxels that directly co-localized with 
cMyBP-C was 71.2 ± 4.1%, a significantly greater value than for non-specific co-localisation 
obtained via geometric rotation of the cMyBP-C image through 90º (38.6 ± 6.7%, p < 0.05) 
(Fig. 4B & S4). The extent of co-localisation between RyR2 and cMyBP-C was independent 
of the immunofluorescent signal intensity corresponding to RyR2 expression levels (Fig. S4). 
 
cMyBP-C modulates RyR2-mediated cellular Ca2+ dynamics 
To ascertain whether cMyBP-C expression influences RyR2-mediated intracellular Ca2+ 
handling, spontaneous Ca2+ release events in HEK293 cells were monitored by confocal 
imaging. N-terminal tagging of cMyBP-C with mCherry (mC-cMyBP-C), which is spectrally 
distinct from fluo-3 Ca2+-reporting dye, enabled visualisation of cells expressing mC-cMyBP-
C. Parallel experiments were completed with two separate cell populations expressing: (1) 
RyR2 & mC-cMyBP-C, and (2) RyR2 & mCherry (Fig. 5 A). Ca2+ transient amplitude (Fig. 5 
B),Ca2+ transient duration (Fig. 5 C), rate of Ca2+ release (Fig. 5D), Ca2+ decay rate (Fig. 5E) 
and ER Ca2+ store content (Fig. 5 G) were unaffected by the presence of mC-cMyBP-C or 
mCherry. The specific distinction between cells expressing RyR2 plus mC-cMyBP-C, relative 
to RyR2 plus mCherry, was a substantial and statistically significant decrease in the number of 
spontaneous Ca2+ oscillations (p < 0.05, Fig. 5F). This reduced propensity for spontaneous 
RyR2-mediated Ca2+ release in the specific presence of mC-cMyBP-C would be consistent 
with an inhibitory role for cMyBP-C on RyR2 channel function. 
 
Discussion 
Excitation-contraction coupling is considered to be a unidirectional process, where the rise in 
intracellular Ca2+ concentration triggered by an action potential induces sarcomere contraction. 
Given that dephosphorylated cMyBP-C is released from the sarcomere in pathological 
conditions (Baker et al., 2015; Decker et al., 2012; Govindan et al., 2012; Kulikovskaya et al., 
2007; Kuster et al., 2014), the structural and functional interaction between the SR-resident 
RyR2 and sarcomere-released, soluble cMyBP-C, described in the present study, may therefore 
constitute an important, previously unrecognised, feedback regulatory mechanism (Fig. 6). Our 
initial observation of RyR2 N-terminus interaction with cMyBP-C C-terminus provided from 
an unbiased transcriptome-wide screen, was further verified by biochemical assays (Fig. 1). 
Parallel experiments with corresponding N-terminal fragment from skeletal muscle isoform 
RyR1 indicated a robust interaction with cMyBP-C (Fig. S2), suggesting that that MyBP-C 
binding might be relevant not only in cardiac, but also in skeletal muscle as well as smooth 
muscle. Importantly, porcine cMyBP-C was found to associate with the cardiac SR subcellular 
endomembranous compartment (Fig. S3) and to co-immunoprecipitate with native porcine 
RyR2 (Fig. 3). Moreover, human cMyBP-C co-localised with RyR2 in HEK293 cells (Fig. 4), 
co-immunoprecipitated with human RyR2 (Fig. 3), and modulated spontaneous RyR2 Ca2+ 
release (Fig. 5). That cMyBP-C dephosphorylation is required for sarcomere dissociation 
(Govindan et al., 2012) suggests that dephosphorylated cMyBP-C should be the form that 
interacts with RyR2. As the functional phosphorylation sites of cMyBP-C are at the N-terminus 
(Moss et al., 2015), while the RyR2 interaction site occurs via the C-terminus, it appears 
unlikely that cMyBP-C phosphorylation would have a direct impact on RyR2 association. 
However, the precise role of cMyBP-C phosphorylation status on specific binding with RyR2 
and it pathophysiological significance remains to be resolved.     
To our knowledge, these observations constitute the first report that suggests a direct role may 
exist for cMyBP-C in the regulation of RyR2-mediated Ca2+ homeostasis. Our data are 
consistent with previous indirect evidence from transgenic mouse models that an altered 
cMyBP-C protein is linked to prolongation of Ca2+ release events (Brickson et al., 2007; 
Pohlmann et al., 2007; Song et al., 2003). While this effect of an altered cMyBP-C could be 
explained by increased myofilament Ca2+ sensitivity (Huke and Knollmann, 2010), a plausible 
alternative or additional mechanism may involve a role for cMyBP-C modulation of a crucial 
Ca2+ signalling component.  
The rate of Ca2+ transient decay is governed by the multilateral involvement of: (1) the SR/ER 
Ca2+/ATPase (SERCA) pumping Ca2+ into the SR, (2) phospholamban inhibiting SERCA 
activity, which could be relieved following phospholamban phosphorylation, (3) the Na+/Ca2+ 
exchanger (NCX) extruding Ca2+ out of the cell, and (4), the SR Ca2+ leak through the RyR2, 
which could be substantial in pathological conditions (Bers, 2002; Bers et al., 2003; George, 
2008). The relative contribution of SERCA is ~92% whereas that of NCX is ~7% for diastolic 
Ca2+ removal in the mouse heart (Bers, 2002). In cMyBP-C knockout mice, RyR2 expression 
and/or channel activity was not investigated but the level of NCX activity was 34% lower 
(Pohlmann et al., 2007), which could partly account for the prolonged Ca2+ transient observed. 
However, the level of phosphorylated phospholamban was 3-fold higher in knockout mouse 
hearts (with unchanged SERCA and phospholamban protein levels) (Pohlmann et al., 2007), 
and therefore reduction in Ca2+ transient duration would be predicted – not an increase. Given 
the 13:1 SERCA (~92%):NCX (~7%) contribution to diastolic Ca2+ removal, the prolonged 
Ca2+ transient seen in cMyBP-C knockout mice appears highly unlikely to be solely due to 
34% lower NCX levels – a notable alternative/additional contribution may be the involvement 
of SR Ca2+ leak through the RyR2. In this scenario, it could be postulated that cMyBP-C is 
normally required to suppress diastolic SR Ca2+ leak through its interaction with RyR2 (Fig. 
6). The putative suppression of RyR2 channel activity by cMyBP-C, interpreted from 
electrically-stimulated Ca2+ transients in cardiomyocytes, is entirely consistent with our 
cMyBP-C co-expression results showing a reduced propensity for RyR2-mediated spontaneous 
Ca2+ transients in a mammalian cell line (Fig. 5), although Ca release event duration was 
unaltered. 
Cardiomyocyte RyR2:cMyBP-C complex formation will depend on the cMyBP-C subcellular 
distribution. As part of the physiological sarcomeric protein turnover, cMyBP-C is known to 
exist as two different forms in vivo, the predominant, phosphorylated form (associated with 
greater thick filament stability) and a second, dephosphorylated form (Moss et al., 2015; 
Sadayappan and de Tombe, 2012). The latter is relatively sensitive to release from the 
sarcomere, with low levels of full-length cMyBP-C reported in the cytosol (Baker et al., 2015; 
Decker et al., 2012; Kuster et al., 2014), which is in agreement with our own observations (Fig. 
S3). Notably, an increased rate of cMyBP-C dephosphorylation, it’s subsequent dissociation 
from the sarcomere and further degradation has been reported in the heart of animal models 
and patients with heart failure, myocardial infarction, ischemia-reperfusion injury and 
pathological hypertrophy (Baker et al., 2015; Decker et al., 2012; Govindan et al., 2012; 
Kulikovskaya et al., 2007; Kuster et al., 2014). Interestingly, high-resolution imaging of 
cMyBP-C and RyR2 revealed that sarcomere-bound cMyBP-C is the predominant form in 
healthy cardiomyocytes (Previs et al., 2015), with significant release of cMyBP-C into the 
cytosol after myocardial infarction/reperfusion (Govindan et al., 2012) and in pathologic 
hypertrophy (Sequiera et al., 2014). Thus, it is plausible that sarcomere-dissociated cMyBP-C 
may be available for RyR2 interaction and modulation of SR Ca2+ release, particularly in the 
above cardiopathologic conditions (Fig. 6). 
The RyR2:cMyBP-C association could also be relevant in DCM and HCM, cardiomyopathies 
often accompanied by an arrhythmogenic phenotype (Maron et al., 2014; Spezzacatene et al., 
2015). RyR2 mutations including those within the N-terminus have recently been linked to 
DCM (Haas et al., 2014), whereas mutations in cMyBP-C are very common in both HCM and 
DCM pathology (Carrier et al., 2015), with some cMyBP-C mutations reported to trigger 
arrhythmic events (Bahrudin et al., 2008; Berul et al., 2001). A proportion of mutations encode 
for cMyBP-C truncated protein(s) that lack the C-terminal C10 domain, a structural element 
critical for association with the thick filament (Flashman et al., 2007) but a domain entirely 
dispensable for RyR2 binding (Fig. 2). It should be noted though that the likely pathogenic 
mechanism of such mutations may be haploinsufficiency, since the predicted cMyBP-C 
truncated polypeptides could not be detected in human patient samples (Carrier et al., 2015; 
Sequeira et al., 2014). Missense mutations (e.g. A31P, E258K) are likely to be expressed and 
incorporated into the myofilaments (De Lange et al., 2013; Harris et al., 2011), whereas a 25-
nucleotide frameshift deletion resulting in a novel sequence within the C10 domain exhibits 
little incorporation into the C-zone of the sarcomere and localises at the Z-line (Kuster et al., 
2015) – a specific location where the RyR2 is found. Interestingly, cMyBP-C mutations 
resulting in truncation have been mostly associated with HCM, whereas missense mutations 
are mostly linked with DCM (Waldmuller et al., 2011). Two different mechanisms underlying 
increased myofilament Ca2+ sensitivity and contractile dysfunction have previously been 
proposed for cMyBP-C truncations and missense mutations, respectively: (1) 
haploinsufficiency that may also involve impairment of nonsense-mediated mRNA decay 
and/or the ubiquitin-proteasome system, and (2) dominant-negative mutant proteins acting as 
poison polypeptides (Carrier et al., 2015; Harris et al., 2011; Sequeira et al., 2014). Our study 
raises the possibility that perturbation of Ca2+ homeostasis due to altered RyR2:cMyBP-C 
interactions may constitute an additional pathogenic mechanism contributing to the 
development of DCM/HCM and/or arrhythmogenicity. Future studies are required to unravel 
the precise molecular mechanism(s) by which MyBP-Cs are involved in possibly dynamic, 
RyR isoform specific regulation of SR Ca2+ release and to fully elucidate the role of 
RyR2:cMyBP-C association in cardiac physiology and disease. 
  
Acknowledgements 
We wish to thank Ajay Sharma and Peter Gapper for contributing excellent technical 
assistance, as well as Wendy Scaccia for essential administrative assistance in the Sir Geraint 
Evans Wales Heart Research Institute.   
 
Competing interest 
None. 
 
Author contribution 
PJS, MS, CHG, SZ designed experiments; PJS, JW, SZ performed experiments; PJS, SZ 
analyzed data and drafted the manuscript; CV, CHG, SZ, FAL revised manuscript that was 
approved and submitted by SZ, FAL. 
 
Funding  
This work was supported by a Wales Heart Research Institute postgraduate research 
scholarship to PJS, British Heart Foundation Fellowship to SZ (Intermediate FS/15/30/31494) 
and Wales Heart Research Institute undergraduate research placement scholarship to JW. 
  
Methods 
Materials 
Mammalian cell culture reagents and Fluo-3 AM were obtained from Thermo Scientific, 
herring testes carrier DNA from Takara, protease inhibitor cocktail (CompleteTM) from Roche, 
nProtein-A Sepharose from GE Healthcare, electrophoresis equipment and reagents from Bio-
Rad, enhanced chemiluminescence detection kit from Thermo Scientific, DNA restriction 
endonucleases from New England Biolabs, Pfu DNA polymerase from Promega, 
oligonucleotides and all other reagents from Sigma unless otherwise stated.  
Antibodies 
Primary antibodies used: rabbit RyR2 specific Ab1093 raised against residues 4454-4474 of 
human RyR2 (used in co-immunoprecipitation (co-IP) at 2 µg and immunofluorescence (IF) at 
1:100 dilution) previously described (Zissimopoulos et al., 2012; Zissimopoulos et al., 2006), 
mouse RyR2 AbP12 raised against residues 2846-2859 of human RyR2 (used in Western 
blotting (WB) at 1:500 dilution, see Fig. S1), sheep cMyBP-C specific AbC-CT (AF7199, R&D 
Systems) raised against mouse cMyBP-C residues 998-1100 (used in WB at 1:200 dilution), 
mouse cMyBP-C specific AbC-NT (E7, Santa Cruz Biotechnology) raised against residues 1-
120 of human cMyBP-C (used in WB at 1:500 dilution and IF at 1:100 dilution), rabbit AbHA 
(Y-11, Santa Cruz Biotechnology; used in co-IP at 2 μg), non-immune rabbit IgG (Santa Cruz 
Biotechnology; used in co-IP at 2 μg), mouse AbHA (16B12, Covance (Biolegend); used in WB 
at 1:1000 dilution), mouse AbcMyc (9E10, Santa Cruz Biotechnology; used in WB at 1:500 
dilution). Secondary antibodies used: goat anti-mouse IgG-horseradish peroxidase conjugate 
(Santa Cruz Biotechnology; used in WB at 1:10000 dilution), donkey anti-sheep IgG-
horseradish peroxidase conjugate (R&D Systems; used in WB at 1:5000 dilution), goat anti-
rabbit IgG-Alexa Fluor 488 conjugate (A-11034, Thermo Scientific; used in IF at 1:500 
dilution), goat anti-mouse IgG-Alexa Fluor 594 conjugate (A-11005, Thermo Scientific; used 
in IF at 1:500 dilution). 
Plasmid constructs 
Plasmids encoding for RyR2 overlapping fragments (BT constructs) tagged with the cMyc 
epitope at the N-terminus were previously described (Zissimopoulos et al., 2013). mCherry 
cDNA was obtained from Addgene and cloned into the mammalian expression vector pCR3 
(Thermo Scientific). Human cMyBP-C cDNA was generated by PCR amplification from a 
human heart cDNA library (Takara) and cloned into pCR3 containing an N-terminal HA 
epitope tag or mCherry fusion protein. Smaller HA-tagged cMyBP-C constructs were 
generated by PCR amplification and cloned in the HA-modified pCR3 vector. Oligonucleotide 
primers and restriction enzyme cloning sites used are given in Table S1. 
Mammalian cell culture 
HEK293 cells (ATCC.org) were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 2 mM glutamine and 10% foetal bovine serum (FBS) in a 37°C humidifying 
incubator with 5% CO2. For use in co-IP, ~1.5 x 10
6 cells were seeded in one 100 mm Petri 
dish a day before transfection in order to be 60-70% confluent the following day. Cells were 
transfected with 24 μg of plasmid DNA using the calcium phosphate precipitation method as 
described elsewhere (Stanczyk et al., 2016). For use in IF, ~0.25 x 106 cells were seeded onto 
poly-lysine coated glass coverslips (22 mm x 22 mm), left to adhere overnight and transfected 
the following day using TurboFect (Thermo Scientific) according to the manufacturer’s 
instructions. For Ca2+ imaging, ~1 x 105 cells were seeded on poly-lysine coated glass bottom 
dishes (MatTek) and transfected using Effectene (Qiagen) according to the manufacturer’s 
instructions.  
Immunofluorescent detection of RyR2 and cMyBP-C 
Transfected HEK293 cells were washed in phosphate buffered saline (PBS) (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4; pH 7.4) and fixed with 4% paraformaldehyde 
for 10 min at room temperature. Fixed cells were washed and re-hydrated with PBS for 1 h 
before permeabilisation with 0.1% Triton X-100 for 30 min. Cells were washed with PBS, 
blocked with 10% FBS for 1 h, and then incubated at room temperature for 2 h with rabbit 
RyR2 specific Ab1093 and mouse cMyBP-C specific AbC-NT antibodies. Samples were then 
washed with PBS and incubated with Alexa488- and Alexa594-conjugated goat-anti rabbit and 
goat anti-mouse antibodies for fluorescent labelling of RyR2 and cMyBP-C, respectively, at 
room temperature for 2 h in the dark. Following final washing with PBS, the coverslips were 
washed in H2O, dried and mounted onto glass slides using ProLong Gold Antifade reagent 
(Thermo Scientific) and stored at 4°C until required. All antibodies were carefully titrated to 
give comparable fluorescent signals under test. There was negligible non-specific fluorescence 
in these cells as determined by using the staining protocol as above but with one or both primary 
and secondary antibodies omitted. 
Image analysis and processing 
Immunofluorescent signals corresponding to RyR2 and cMyBP-C were visualised using a 
confocal microscope (SP5, Leica Microsystems) fitted with an 63X oil immersion objective 
(NA 1.4). Signal intensity in the images were adjusted to the full dynamic range using the 
operating software’s ‘glow-over’ function (LAS-AF, Leica Microsystems) and were collected 
throughout the depth of each samples (z-stack 0.5 µm slices, 18.5 ± 0.24 frames, and average 
depth of cell 8.6 ± 1.2 µm). Individual z-plane images were recombined into three-dimensional 
datasets using LAS-AF (Leica Microsystems). Data were imported into Imaris (Bitplane, 
Andor Technology) and the signal threshold for bona-fide RyR2 and cMyBP-C positive voxels 
in each image was defined using the levels of non-specific immunofluorescence established as 
above. Over the entire dataset (n = 192 3D reconstructions from 4 separate transfections), 
RyR2- and cMyBP-C positive voxels were assigned to 2.8 ± 0.1% and 7.8 ± 0.3% of the total 
voxels, respectively. In each z-stack, the proportion of RyR2 voxels that were spatially co-
incident with cMyBP-C voxels was calculated using Imaris. Normally-distributed data were 
subjected to statistical testing using unpaired two-tailed Student’s t-test and non-normally 
distributed data were tested using an unpaired Mann-Witney test. Linear regression and the 
calculation of Pearson’s correlation coefficient (PCC) was performed (Microsoft Excel, Office 
2016). A p value <0.05 was taken as significant. 
Other methodologies 
The Y2H system (Lam et al., 2013; Stanczyk et al., 2016; Zissimopoulos et al., 2006), co-IP 
and WB (Stanczyk et al., 2016; Zissimopoulos et al., 2012; Zissimopoulos et al., 2013), cardiac 
SR preparation (Zissimopoulos et al., 2012), and single cell Ca2+ imaging (Handhle et al., 2016; 
Seidel et al., 2015b) were carried out as previously described. Densitometry analysis was 
carried out using GS700 densitometer (Bio-Rad) and Quantity-one (Bio-Rad) software. 
Microsoft Excel was used to store and plot numerical data (expressed as mean ± SEM), unless 
otherwise stated. Statistical analysis was performed using GraphPad prism (GraphPad 
Software Inc). Data were first subjected to the Brown-Forsythe test for the equality of group 
variances, and populations with equal variance (no significantly different standard deviations, 
p < 0.05) were analysed using one-way ANOVA (with Bonferroni's post-test). Where data were 
non-normally distributed, the Kruskal-Wallis test (with Dunn's multiple comparisons test) was 
used. 
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 Table 1 
Y2H -galactosidase assay for (AD fusion) cMyBP-C interaction with RyR2 overlapping 
(DNA-BD fusion) BT constructs (+++ denotes strong interaction, – denotes no interaction). 
 
 
  
 BT4L 
(1-
906) 
BT3 
(677-
1621) 
BT5 
(1563-
2507) 
BT6 
(2346-
3131) 
BT7 
(3071-
3940) 
BT71 
(3788-
4204) 
BT1A2 
(3995-
4499) 
BT1B 
(4596-
4715) 
BT1B2 
(4596-
4765) 
BT8 
(4867-
4967) 
AD/cMyBP-C 
(817-1274) 
+++ - - - - - - - - - 
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Figure 1. cMyBP-C C-terminus interaction with RyR2 N-terminus 
Co-IP assays from HEK293 cells co-expressing BT4L (cMyc-tagged RyR2 residues 1-906) or 
BT7 (cMyc-tagged RyR2 residues 3071-3940) together with HA-tagged cMyBP-C CT 
(residues 817-1274) (A), FL (full-length) (B), or NT (residues 1-866) (C). HA-cMyBP-C 
constructs were immunoprecipitated with AbHA from solubilised cell lysates and the presence 
of co-precipitated BT4L/BT7 was analysed by WB using AbcMyc (top). To detect immuno-
isolated HA-cMyBP-C, 1/10th of IP samples was analysed by WB using AbHA (bottom). Non-
immune rabbit IgG served as negative control (non-specific binding). An aliquot of HEK293 
cell lysate corresponding to 0.5% of the amount processed in the co-IP assay was included in 
the gels to assess protein expression. (D) Data summary (n ≥ 5) following densitometry analysis 
and normalisation to each construct’s respective lysate (taken as 100%); data are given as mean 
value ± SEM. Statistical analysis was carried out using paired, 2-tailed Student’s t test (* p < 
0.05). 
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Figure 2. Mapping of RyR2 and cMyBP-C binding sites 
Schematic diagram of (HA-tagged) constructs covering cMyBP-C carboxyl-terminus (A) and 
RyR2 amino-terminus (cMyc-tagged) BT sub-fragments (C). Co-IP assays from HEK293 cells 
co-expressing BT4L with HA-cMyBP-C constructs (B), or cells co-expressing BT constructs 
with HA-cMyBP-C/CT (D). Data summary (n = numbers for each data set: (left) 9/CT; 3/C6-
C8, 8/C8-C10, 3/fC6-C7, 4/C6-C7, 6/C8-C9, 4/C9-C10, 8/fC6, 7/C7, 8/C8, 7/C9; (right) 
9/BT4L, 4/BT4, 7/BT4A, 7/BT4B, 5/BT4C, 6/BT4D, 7/BT4BL, 4/BT4DL, 7/BT4EL) 
following quantitative densitometry analysis and normalisation to each construct’s respective 
lysate (taken as 100%); data are given as mean value ± SEM. Statistical analysis was carried 
out using paired, 2-tailed Student’s t test (* p < 0.05).  
Figure 3 
 
 
Figure 3. Native pig and recombinant human RyR2:cMyBP-C interaction 
Co-IP assays from pig cardiac tissue (A) or HEK293 cells co-expressing full-length human 
RyR2 with human cMyBP-C/FL (C). RyR2 was immunoprecipitated with Ab1093 from 
solubilised pig cardiac (A) or HEK293 cell lysate (C), and the presence of co-precipitated 
cMyBP-C was analysed by WB using AbC-CT or AbHA, respectively (top). To detect immuno-
isolated RyR2, 1/10th of IP samples was analysed by WB using AbP12 (bottom). Non-immune 
rabbit IgG served as negative control (non-specific binding). An aliquot of cell lysate 
corresponding to 0.5% of the amount processed in the co-IP assay was included in the gels to 
assess protein expression. (B, D) Data summary (n = 5) following densitometry analysis and 
normalisation to the lysate (taken as 100%); data are given as mean value ± SEM. Statistical 
analysis was carried out using paired, 2-tailed Student’s t test (* p < 0.05). 
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 Figure 4. Subcellular co-localisation of RyR2 with cMyBP-C in HEK293 cells 
(A) Representative images of the intracellular distribution of heterologous RyR2 (green) and 
cMyBP-C (red) in a single HEK293 cell. Composite images were generated in which spatially 
co-localised voxels corresponding to RyR2 and cMyBP-C were overlaid (yellow). The 
corresponding bright-field image of the cell is also given (BF). 
(B) The extent of RyR2 co-localisation with cMyBP-C was quantified. Non-specific co-
localisation was assessed following geometric rotation of the cMyBP-C image through 90º 
(see also Fig. S4). The data on RyR2:cMyBP-C co-localisation are plotted as mean value ± 
SEM and are from analysis of 192 cells from 4 separate experiments. The values resulting 
from the rotation of cMyBP-C images through 90º are given as mean value ± SEM and are 
from the analysis of 10 randomly selected images. 
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Figure 5. cMyBP-C alters RyR2-mediated Ca2+ handling in HEK293 cells 
Single cell Ca2+ imaging using confocal laser scanning microscopy to monitor spontaneous 
intracellular Ca2+ mobilisation. Representative traces (left, A) and summary of results (right B-
G) from cells expressing RyR2 plus mC-cMyBP-C (n = 70), or RyR2 plus mCherry (n = 33). 
To estimate cell ER load, 10 mM caffeine was added after 2 min 30 sec and recorded for further 
30 sec. Parameters of Ca2+ release events analysed include amplitude (B), duration (C), rate of 
release (D), rate of decay (E), frequency (F), Ca2+ store content (G). Data are normalised for 
RyR2 alone and are presented as mean value ± SEM. Statistical analysis was carried out using 
one-way ANOVA with Bonferroni's multiple comparisons test (B, C, D, E) or Kruskal-Wallis 
test with Dunn's multiple comparisons test ( F,G) (* p < 0.05). 
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 Figure 6. Working hypothesis for retrograde regulation of SR Ca2+ release by the 
sarcomere 
In the healthy heart, an action potential triggers a transient rise in the intracellular Ca2+ 
concentration, which in turns induces sarcomere contraction. cMyBP-C is in its phosphorylated 
form and predominantly associated with myofilaments, where it regulates acto-myosin cross-
bridge formation. In pathological conditions associated with SR Ca2+ leak leading to 
intracellular Ca2+ overload, dephosphorylated cMyBP-C translocates from the sarcomere to the 
SR, where it suppresses Ca2+ leak through its interaction with RyR2 facilitating normal Ca2+ 
homeostasis and contraction. (AP: action potential, LTCC: L-type Ca2+ channel, NCX: 
Na+/Ca2+ exchanger, PLN: phospholamban, SERCA: SR/ER Ca2+ ATPase). 
 
